The schizophrenia drug Emraclidine failed to perform in clinical trials but executives say it can still “play a role.” ...
AbbVie will commit "less capital" towards experimental medicines for psychiatric disease, CEO Robert Michael said at an ...
AbbVie's strong financials and potential for cash flow make it a valuable investment, despite risks from patent expirations.
AbbVie said the impairment charge is related to last year’s $8.7 billion bet on Cerevel following the failure of the deal’s ...
By Sneha S K and Christy Santhosh (Reuters) -AbbVie plans to "commit less capital" towards experimental medicines for ...
As the J.P. Morgan Healthcare Conference started in San Francisco on Monday, AbbVie linked up with Simcere with a $1 billion ...
AbbVie said it would take a $3.5 billion dollar impairment charge related to the failure of a drug it acquired in its ...
Abbvie said on Friday it would record a charge of about $3.5 billion related to its experimental schizophrenia drug, ...
The failure of Cerevel's emraclidine in schizophrenia will cost AbbVie an impairment charge of about $3.5 billion, the pharma ...
Sasanlimab, a subcutaneous immunotherapy developed by Pfizer, could help treat bladder cancer. Elsewhere, Royalty Pharma ...